Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

by | Dec 17, 2024 | Business

Duvakitug was generally well tolerated across patient groups and showed similar rates of treatment-emergent adverse events, according to the companies.

Article Attribution | Read More at Article Source